2024 ATS Onsite Highlights - 20

SCHEDULE AT A GLANCE
INDUSTRY EVENTS
INNOVATION THEATER INNOVATION HUB EVENING SYMPOSIA
SUNDAY, MAY 19
11:30 a.m.-12 p.m.
When It Could Be Cystic Fibrosis (CF):
Diagnosing CF in People with Atypical
Disease Presentation
Vertex Pharmaceuticals, Inc.
Innovation Theater 1
11:35-11:55 a.m.
Silent No More - Uncovering the Role of
Small Airways in Asthma
Chiesi
Innovation Hub 3
12-12:30 p.m.
Should We Be Targeting Eosinophils
Regardless of Allergic Status in Patients
With Severe Eosinophilic Asthma?
GSK
Innovation Theater 2
12:35-12:55 p.m.
Embracing the Changes: New Horizons in
Asthma Clinical Trials
Parexel
Innovation Hub 4
1-1:30 p.m.
A Brief Review of Clinical Insights for
Identifying and Managing Patients
With Eosinophilic Granulomatosis With
Polyangiitis (EGPA)
GSK
Innovation Theater 2
1:15-1:35 p.m.
Challenges in Diagnosing Refractory
Chronic Cough
GSK
Innovation Hub 2
1:30-2:15 p.m.
Disease Characteristics, Treatments, and
Outcomes: Recent Findings From a Large,
Real-World, PAH Drug Registry
Johnson & Johnson
Innovation Theater 1
11:30 a.m.-12:15 p.m.
What Can the Future Hold for Your
Patients With Severe Asthma?
AstraZeneca
Innovation Theater 3
11:30 a.m.-12:30 p.m.
Clinical and patient-centered discussions
on the role of inflammation in
bronchiectasis
Insmed Incorporated
Innovation Theater 5
11:55 a.m.-12:15 p.m.
Advances in Ventilation and Perfusion (VQ) Assessment in COPD, CTEPH and Other
Chronic Pulmonary Vascular Disorders
4D Medical
Innovation Hub 4
12:15-12:25 p.m.
Elevating Asthma Control: Implications for
Your Pediatric Patients
sanofi | regeneron
Innovation Hub 1
12:55-1:15 p.m.
EVIS X1 with Prof. Felix Herth, MD
Olympus America Inc.
Innovation Hub 1
1-1:45 p.m.
Navigating RSV in Adults: Insights into
Disease and Vaccination
GSK
Innovation Theater 3
1:15-1:35 p.m.
Clearing the air: Navigating the diagnosis
and management of Bronchiolitis obliterans
syndrome (BOS) after lung transplant
Zambon USA Ltd.
Innovation Hub 4
1:35-1:55 p.m.
The heterogeneity of COPD pathophysiology
and the role of PDE inhibition: focus
on inflammation
Verona Pharma Inc
Innovation Hub 1
6:30-8 p.m.
Stories Behind the Science in Non-Cystic Fibrosis
Bronchiectasis: Understanding Disease Burden, Diagnosing
Early, and Looking Toward New Management Options
PVI, PeerView Institute for Medical Education
Marriott Marquis - Marina Ballroom F/G
6:30-9:30 p.m.
Approaches to COPD care: Targeting the ST2
receptor and IL-33 pathway as a potential
option for patients at risk of exacerbating
Genentech
Hilton Bayfront - Sapphire Ballroom
12:30-1 p.m.
Implementing Treprostinil Induction
Strategies in Pulmonary Arterial
Hypertension
United Therapeutics
Innovation Theater 1
12:55-1:15 p.m.
How Methapharm Leverages Market Data
for Strategic Growth
AcuityMD
Innovation Hub 3
1-2 p.m.
How Would You Address Eosinophilic +
Allergic Inflammation in Severe Asthma?
Amgen/AstraZeneca
Innovation Theater 5
1:15-2 p.m.
Pulmonary Alveolar Proteinosis:
Pathophysiology, Diagnosis, and
Management
Savara Inc.
Innovation Theater 4
1:35-1:55 p.m.
Tools of the Trade: Imaging in ILD
Boehringer Ingelheim Pharmaceuticals,
Inc.
Innovation Hub 3
6:30-9:30 p.m.
A Recent Development for Adults with Pulmonary Arterial
Hypertension
Merck & Co., Inc.
Manchester Grand Hyatt - Grand Hall
6:30-9:30 p.m.
Epithelial Cytokines: Connecting the Dots
in Severe Asthma, Nasal Polyps, and COPD
Amgen/AstraZeneca
Hilton Bayfront - Indigo Ballroom
6:30-9:30 p.m.
Asymmetrical Nasal High Flow: A
New Paradigm in Noninvasive
Respiratory Support
Fisher & Paykel Healthcare Inc.
Manchester Grand Hyatt - Seaport Ballroom
20
ATS 2024 International Conference
2024 ATS Onsite Highlights

Table of Contents for the Digital Edition of 2024 ATS Onsite Highlights
